Chronic gut inflammation can become self-reinforcing: damaged tissue produces reactive oxygen species (ROS) and inflammatory signals, which draw in immune cells that can cause further injury.
Researchers adapted glutaraldehyde-functionalized glass to hold living bacteria firmly enough for nanometer-resolution atomic force microscopy while preserving high viability and, in one E. coli experiment, continued growth and division. The method enabled comparisons across bacterial species, LPS compositions, and cell orientations, revealing differences in outer membrane structure and growth-phase-dependent changes at bacterial poles.
Researchers developed a PLZ4-targeted, transformable peptide nanoparticle that carries the doxorubicin prodrug Leu-DOX and releases it in response to MMP9 in the tumor microenvironment. In cell studies and mouse models of bladder cancer, the platform increased tumor drug retention and produced stronger antitumor effects with fewer measured signs of doxorubicin toxicity, supporting further preclinical investigation.
Researchers developed hydro/nano-bFGF, a two-stage delivery system that combines an enzyme-responsive, cartilage-adhesive hydrogel with bFGF-loaded nanocapsules to improve drug retention, cartilage penetration, and growth factor release near chondrocytes. In human osteoarthritic cartilage explants and rodent models, the system improved matrix regeneration, cartilage structure, and joint function, while long-term safety and clinical effectiveness remain to be determined in future studies.
Researchers created iSOD, a superoxide dismutase-templated ultrasmall iron oxide nanozyme that combines antioxidant activity with MRI contrast for liver fibrosis. In rat models, iSOD reduced collagen deposition and produced fibrosis-associated MRI signal differences, although larger studies and quantitative imaging validation are still needed.
Researchers developed a carboxymethyl cellulose-based immunonanosystem containing cobalt-substituted magnetite nanoparticles and anti-CD44 antibodies to target glioblastoma cells through enzyodynamic ferroptosis and photothermal therapy. In 2D cell cultures and 3D gliomaspheres, the system showed preferential activity against CD44-expressing glioblastoma cells, supporting further preclinical studies of its safety, delivery, and therapeutic performance.
Researchers developed NMm@MINO, a minocycline-loaded gelatin nanoparticle coated with hybrid neutrophil–macrophage membranes to tackle bacterial infection, inflammation, and periodontal tissue damage. In laboratory and rat experiments, the platform killed bacteria, altered inflammatory responses, promoted osteogenesis-associated processes, suppressed osteoclast activity, and reduced alveolar bone loss.
Researchers developed glutathione-responsive EONPs that co-deliver STING and DHODH inhibitors to reprogram macrophage inflammatory metabolism in experimental sepsis. In mouse models, the treatment reduced inflammation and organ injury, improved short-term survival, and altered gut microbial metabolism, with 5-HIAA contributing to the immune response.
Researchers developed diimmonium DB·2X nano-agents that support photoacoustic imaging at 1700 nm, with DB·2TFSI showing strong performance in preclinical imaging experiments. In mouse models, 1700 nm imaging reduced endogenous background interference and improved signal-to-background ratios compared with 1064 nm, supporting further investigation of NIR-IIb photoacoustic contrast agents.
Researchers developed a rapid, one-pot method that used sunlight and a commercial vincristine formulation to form gold nanoparticles within five minutes without separate reducing or stabilizing agents. The particles retained vincristine’s antiproliferative activity against Colo-205 colon cancer cells and showed greater DPPH radical scavenging than free vincristine at several tested concentrations, while questions about drug photostability, release, stability, and in vivo performance remain.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.